Isoray - ISR Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Isoray in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ISR shares.
View ISR analyst ratings or view top-rated stocks.

1 brokerages have issued 12-month price targets for Isoray's stock. Their ISR share price forecasts range from $1.25 to $1.25. On average, they anticipate the company's share price to reach $1.25 in the next year. This suggests a possible upside of 237.7% from the stock's current price.
View analysts price targets for ISR or view top-rated stocks among Wall Street analysts.

Isoray's stock was trading at $0.38 at the beginning of the year. Since then, ISR shares have decreased by 2.6% and is now trading at $0.3701.
View the best growth stocks for 2022 here.

Isoray is scheduled to release its next quarterly earnings announcement on Monday, September 19th 2022.
View our ISR earnings forecast.

Isoray, Inc. (NYSEAMERICAN:ISR) posted its quarterly earnings data on Wednesday, November, 10th. The healthcare company reported ($0.02) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by $0.01. The healthcare company earned $2.56 million during the quarter, compared to the consensus estimate of $2.58 million. Isoray had a negative trailing twelve-month return on equity of 9.19% and a negative net margin of 48.05%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Isoray investors own include Brainstorm Cell Therapeutics (BCLI), OPKO Health (OPK), Bausch Health Companies (BHC), Anavex Life Sciences (AVXL), TherapeuticsMD (TXMD), Catalyst Pharmaceuticals (CPRX), MannKind (MNKD), CTI BioPharma (CTIC), Idera Pharmaceuticals (IDRA) and Palatin Technologies (PTN).

Isoray trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ISR."

Isoray's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Perkins Capital Management Inc. (2.05%) and Taylor & Morgan Wealth Management LLC (0.55%). Insiders that own company stock include Jonathan Robert Hunt, Lori A Woods, Mark John Austin, Michael Krachon, Philip J Vitale and William Cavanagh.
View institutional ownership trends.

Shares of ISR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ISR stock can currently be purchased for approximately $0.37.

Isoray (NYSEAMERICAN:ISR) has a market capitalization of $52.57 million and generates $10.05 million in revenue each year. The healthcare company earns $-3,390,000.00 in net income (profit) each year or ($0.05) on an earnings per share basis.

Isoray employs 61 workers across the globe.

Isoray's mailing address is 350 Hills St Ste 106, RICHLAND, WA 99354-5511, United States. The official website for the company is isoray.com. The healthcare company can be reached via phone at (509) 375-1202, via email at dbabcock@isoray.com, or via fax at 509-267-3670.